195 related articles for article (PubMed ID: 32652753)
1. Successful Treatment of Patients with Refractory High-Grade Serous Ovarian Cancer with GOPC-ROS1 Fusion Using Crizotinib: A Case Report.
Dong D; Shen G; Da Y; Zhou M; Yang G; Yuan M; Chen R
Oncologist; 2020 Nov; 25(11):e1720-e1724. PubMed ID: 32652753
[TBL] [Abstract][Full Text] [Related]
2. ROS1-ADGRG6: a case report of a novel ROS1 oncogenic fusion variant in lung adenocarcinoma and the response to crizotinib.
Xu S; Wang W; Xu C; Li X; Ye J; Zhu Y; Ge T
BMC Cancer; 2019 Aug; 19(1):769. PubMed ID: 31382924
[TBL] [Abstract][Full Text] [Related]
3. Novel SLC12A2-ROS1 Fusion in Non-Small Cell Lung Cancer with a Significant Response to Crizotinib: The Importance of Choosing the Appropriate Next-Generation Sequencing Assay.
Rodríguez-Antolín C; Rosas-Alonso R; Cruz P; Higuera O; Sánchez-Cabrero D; Esteban-Rodríguez I; Peláez-García A; Fernández Montaño VE; Rodríguez-Jiménez C; Ibáñez de Cáceres I; de Castro J
Oncologist; 2021 Jun; 26(6):e908-e912. PubMed ID: 33682977
[TBL] [Abstract][Full Text] [Related]
4. ROS1 genomic rearrangements are rare actionable drivers in microsatellite stable colorectal cancer.
Akhoundova D; Hussung S; Sivakumar S; Töpfer A; Rechsteiner M; Kahraman A; Arnold F; Angst F; Britschgi C; Zoche M; Moch H; Weber A; Sokol E; Fritsch RM
Int J Cancer; 2022 Dec; 151(12):2161-2171. PubMed ID: 36053834
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of Crizotinib among Different Types of ROS1 Fusion Partners in Patients with ROS1-Rearranged Non-Small Cell Lung Cancer.
Li Z; Shen L; Ding D; Huang J; Zhang J; Chen Z; Lu S
J Thorac Oncol; 2018 Jul; 13(7):987-995. PubMed ID: 29704675
[TBL] [Abstract][Full Text] [Related]
6. Identification of a novel WNK1-ROS1 fusion in a lung adenocarcinoma sensitive to crizotinib.
Liu Y; Liu T; Li N; Wang T; Pu Y; Lin R
Lung Cancer; 2019 Mar; 129():92-94. PubMed ID: 30797499
[TBL] [Abstract][Full Text] [Related]
7. Cabozantinib overcomes crizotinib resistance in ROS1 fusion-positive cancer.
Katayama R; Kobayashi Y; Friboulet L; Lockerman EL; Koike S; Shaw AT; Engelman JA; Fujita N
Clin Cancer Res; 2015 Jan; 21(1):166-74. PubMed ID: 25351743
[TBL] [Abstract][Full Text] [Related]
8. Clinical significance of ROS1 5' deletions in non-small cell lung cancer.
Capizzi E; Dall'Olio FG; Gruppioni E; Sperandi F; Altimari A; Giunchi F; Fiorentino M; Ardizzoni A
Lung Cancer; 2019 Sep; 135():88-91. PubMed ID: 31447007
[TBL] [Abstract][Full Text] [Related]
9. Identification of a Novel MAN1A1-ROS1 Fusion Gene Through mRNA-based Screening for Tyrosine Kinase Gene Aberrations in a Patient with Leiomyosarcoma.
Suehara Y; Kohsaka S; Hayashi T; Akaike K; Kurisaki-Arakawa A; Sato S; Kobayashi E; Mizuno S; Ueno T; Morii T; Okuma T; Kurihara T; Hasegawa N; Sano K; Sasa K; Okubo T; Kim Y; Mano H; Saito T
Clin Orthop Relat Res; 2021 Apr; 479(4):838-852. PubMed ID: 33196586
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of Crizotinib Treatment in a Patient With Unresectable GOPC-ROS1 Fusion Agminated Spitz Nevi.
Robertson SJ; Orme L; Teixeira R; Shamassi M; Newell F; Patch AM; Yeh I; Gard G; Wilmott J; Jackett L; LeBoit P; Fellowes A; MacArthur G; Fox S; Hayward NK; Bastian B; Scolyer R; Waddell N; Penington A; Shackleton M
JAMA Dermatol; 2021 Jul; 157(7):836-841. PubMed ID: 34076666
[TBL] [Abstract][Full Text] [Related]
11. GOPC-ROS1 Fusion Due to Microdeletion at 6q22 Is an Oncogenic Driver in a Subset of Pediatric Gliomas and Glioneuronal Tumors.
Richardson TE; Tang K; Vasudevaraja V; Serrano J; William CM; Mirchia K; Pierson CR; Leonard JR; AbdelBaki MS; Schieffer KM; Cottrell CE; Tovar-Spinoza Z; Comito MA; Boué DR; Jour G; Snuderl M
J Neuropathol Exp Neurol; 2019 Dec; 78(12):1089-1099. PubMed ID: 31626289
[TBL] [Abstract][Full Text] [Related]
12. Molecular Changes Associated with Acquired Resistance to Crizotinib in ROS1-Rearranged Non-Small Cell Lung Cancer.
Song A; Kim TM; Kim DW; Kim S; Keam B; Lee SH; Heo DS
Clin Cancer Res; 2015 May; 21(10):2379-87. PubMed ID: 25688157
[TBL] [Abstract][Full Text] [Related]
13. Crizotinib presented with promising efficacy but for concomitant mutation in next-generation sequencing-identified ROS1-rearranged non-small-cell lung cancer.
Zeng L; Li Y; Xiao L; Xiong Y; Liu L; Jiang W; Heng J; Qu J; Yang N; Zhang Y
Onco Targets Ther; 2018; 11():6937-6945. PubMed ID: 30410351
[TBL] [Abstract][Full Text] [Related]
14. Crizotinib-Resistant ROS1 Mutations Reveal a Predictive Kinase Inhibitor Sensitivity Model for ROS1- and ALK-Rearranged Lung Cancers.
Facchinetti F; Loriot Y; Kuo MS; Mahjoubi L; Lacroix L; Planchard D; Besse B; Farace F; Auger N; Remon J; Scoazec JY; André F; Soria JC; Friboulet L
Clin Cancer Res; 2016 Dec; 22(24):5983-5991. PubMed ID: 27401242
[TBL] [Abstract][Full Text] [Related]
15. Case report: Successful sequential therapy of crizotinb and entrectinib in ROS1-positive non-small-cell lung cancer with brain metastasis in later-settings.
Dong W; Zhuge J; Yu P; Liu K; Yang M; Wang H
Medicine (Baltimore); 2023 Dec; 102(51):e36591. PubMed ID: 38134118
[TBL] [Abstract][Full Text] [Related]
16. Different Types of
He Y; Sheng W; Hu W; Lin J; Liu J; Yu B; Mao X; Zhang L; Huang J; Wang G
Oncol Res; 2019 Aug; 27(8):901-910. PubMed ID: 30940295
[No Abstract] [Full Text] [Related]
17. A case of lung adenocarcinoma with a novel CD74-ROS1 fusion variant identified by comprehensive genomic profiling that responded to crizotinib and entrectinib.
Hashiguchi MH; Sato T; Watanabe R; Kagyo J; Matsuzaki T; Domoto H; Kato T; Nakahara Y; Yokose T; Hiroshima Y; Shiomi T
Thorac Cancer; 2021 Sep; 12(18):2504-2507. PubMed ID: 34319660
[TBL] [Abstract][Full Text] [Related]
18. Targeting ROS1 Rearrangements in Non-small Cell Lung Cancer: Crizotinib and Newer Generation Tyrosine Kinase Inhibitors.
Morris TA; Khoo C; Solomon BJ
Drugs; 2019 Aug; 79(12):1277-1286. PubMed ID: 31313100
[TBL] [Abstract][Full Text] [Related]
19. An Activating KIT Mutation Induces Crizotinib Resistance in ROS1-Positive Lung Cancer.
Dziadziuszko R; Le AT; Wrona A; Jassem J; Camidge DR; Varella-Garcia M; Aisner DL; Doebele RC
J Thorac Oncol; 2016 Aug; 11(8):1273-1281. PubMed ID: 27068398
[TBL] [Abstract][Full Text] [Related]
20. CEP72-ROS1: A novel ROS1 oncogenic fusion variant in lung adenocarcinoma identified by next-generation sequencing.
Zhu YC; Zhou YF; Wang WX; Xu CW; Zhuang W; Du KQ; Chen G
Thorac Cancer; 2018 May; 9(5):652-655. PubMed ID: 29517860
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]